Associate Professor, Department of Human Microbiology
Sackler School of Medicine
Tel Aviv University
Tel Aviv, Israel
Seeking to develop novel strategies to reduce drug resistance and metastasis in aggressive breast cancers.
Laboratory studies are conducted to test a new drug target for combination therapy in triple negative breast cancers.
This research may identify predictive biomarkers of response to targeted therapies and novel new combination approaches to counter drug resistance and prevent metastasis.
For a tumor to spread (a process called metastasis), tumor cells must be able to break through tissue barriers, enter the circulation, and become established in a new site. To achieve these steps, a tumor cell must acquire unique physical and molecular properties.
The research team of Drs. Tsarfaty, Vande Woude, and Graveel have combined several unique laboratory models to evaluate how the Met oncogene influences breast cancer metastasis, metabolism, and drug resistance in HER2+ and triple negative breast cancers (TNBC). Their recent studies have identified potential combination approaches that could reduce drug resistance and prevent metastasis in these diseases.
The research team continues to study the role of Met in progression of HER2+ and triple negative breast cancer using a combination of novel imaging techniques and mathematical models and plan to test combination therapies against TNBC progression and metastasis in patient-derived TNBC models.
This research will enable development of novel molecular and imaging signatures, identify predictive biomarkers in patients who are responsive to Met-targeted therapies, and lead to the development of novel combination therapies.
Dr. Ilan Tsarfaty received his BSc. (1983), MSc. (1986) and PhD (1990) from Tel Aviv University. From 1991-1994, he served as a postdoctoral research associate at the National Cancer Institute's Frederick Cancer Research and Development Center. He was a visiting scientist at the Van Andel Research Institute Grand Rapids MI as a part of the Molecular Imaging Center University of Michigan (2001 - 2003). Dr. Tsarfaty has been a member of the Department of Clinical Microbiology and Immunology, Sackler School of Medicine, Tel Aviv University since 1994. He is the author of over 50 scientific research articles and over 10 books chapters. Dr. Tsarfaty cloned the gene of the breast cancer antigen Muc1 and showed its potential use as a marker for breast cancer. He was the first to show that the Met tyrosine kinase growth factor receptor is involved in tubule formation in mammary tubule and in mesenchymal epithelial cell conversion.
Dr. Tsarfaty was the first to show that Met is a prognostic factor for breast cancer patients. He also showed that HGF/SF alters metabolic activity by induction of Mimp a novel gene that is involved in metastasis that was cloned and characterize in Dr. Tsarfaty's lab. Dr. Tsarfaty has been leading an effort to develop noninvasive breast tumor molecular imaging modalities as a powerful tool in understanding the metabolic activity induced by Met signal transduction. This technology enhances definition of tumor margins and may allow earlier detection of smaller tumor and small metastatic lesions. Currently, Dr. Tsarfaty's lab is in the process of understanding the physical, cellular and molecular mechanism of Met induced motility leading to embryo development and metastasis.